However, combined SST2- and SST5-selective analog treatment to activate both receptor subtypes produced greatly enhanced suppression of GH, thus supporting the concept that greater activity at SST5 is required to normalize GH in a greater percentage of acromegaly patients than is achieved with lanreotide and octreotide (Jaquet et al., 2000). Here, GH1 is linked to acromegaly.